Clinical trial Recruiting at 9 sites Interventional Ages 18 and up Men only

Predicting toxicity from radiotherapy after breast cancer surgery and reconstruction

Official title: Prospective Evaluation of a Predictive Toxicity Test Post Radiotherapy After Mastectomy With Immediate Implant Reconstruction

Run by Institut du Cancer de Montpellier - Val d'Aurelle · NCT04342546 · Data updated 2026-11-12

This study is testing a new test to see if it can help identify breast cancer patients who might experience severe side effects from radiation after surgery and reconstruction, so they can receive better care.

More Breast Cancer trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment250 (estimated)
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
Academic / other
Drugs / interventionsradiation
Locations9 sites (Dijon and 8 other locations)
StatusRecruiting
StartedDecember 11, 2020
Main results expectedDecember 10, 2029
Study endsDecember 10, 2031
Registry record updatedApril 13, 2026
Trial IDNCT04342546 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include women aged 18 and older with histologically confirmed breast cancer who are undergoing mastectomy and are eligible for immediate breast reconstruction with implants.

Probably not a fit

Patients with inflammatory breast cancer, metastatic disease, or those requiring flap reconstruction will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the NovaGray RILA Breast® test's ability to predict the toxicity associated with radiotherapy following mastectomy and immediate breast implant reconstruction. It aims to identify patients at high risk for severe side effects from radiotherapy, which can negatively impact cosmetic outcomes and quality of life. By assessing T-CD8 lymphocyte apoptosis, the study seeks to personalize treatment strategies and potentially reduce unnecessary surgeries for low-risk patients. The goal is to improve patient care and outcomes in breast cancer treatment.

Why it matters

Potential benefit: If successful, this study could lead to more personalized treatment plans that minimize the risk of severe side effects from radiotherapy in breast cancer patients.

How similar studies have gone: Other studies have shown promise in using predictive tests for radiotherapy toxicity, but this specific approach with the NovaGray RILA Breast® test is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥18 years
* Patients with histologically confirmed breast cancer with indication of mastectomy or surgery with mastectomy performed
* Indication of wall chest radiation after mastectomy
* Patient's agreement to receive or having had an immediate breast reconstruction by implant in one or two steps, with or without a dermal or synthetic matrix (depending on the habits of the center)
* Performance Status 0-1
* Consent signed before any study procedure
* Patient geographically accessible for follow-up
* Affiliated to the French national social security system

Exclusion Criteria:

* Breast reconstruction with flap
* Inflammatory breast cancer (cT4d)
* Skin or parietal breast cancer (cT4 a, b or c)
* Metastatic patients
* Patients with bilateral breast cancer
* History of homolateral breast cancer treated with radiotherapy
* History of contralateral breast cancer
* Pregnant or breastfeeding women
* Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent
* Participation in an interventional clinical study or planned participation during study up to 12 months post-radiotherapy

Where it's running

  • Centre Georges François Leclerc
    Dijon, France
    Recruiting
  • Centre Oscar Lambret
    Lille, France
    Recruiting
  • Centre Léon Bérard
    Lyon, France
    Recruiting
  • Institut Paoli Calmette
    Marseille, France
    Recruiting
  • Institut du Cancer de Montpellier
    Montpellier, France
    Recruiting
  • centre Antoine Lacassagne
    Nice, France
    Recruiting
Show 3 more locations
  • Hôpital Tenon
    Paris, France
    Recruiting
  • Institut de Cancérologie de l'Ouest
    Saint-Herblain, France
    Recruiting
  • Institut Claudius Regaud
    Toulouse, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.